Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 315,900 shares, a decrease of 5.2% from the March 15th total of 333,400 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average daily volume of 562,100 shares, the short-interest ratio is currently 0.6 days.

Hookipa Pharma Price Performance

Shares of Hookipa Pharma stock opened at $0.76 on Thursday. The firm has a market cap of $75.45 million, a PE ratio of -0.87 and a beta of 1.02. Hookipa Pharma has a 1 year low of $0.41 and a 1 year high of $2.05. The stock has a fifty day moving average price of $0.73 and a 200-day moving average price of $0.65.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The business had revenue of $7.41 million during the quarter, compared to the consensus estimate of $3.60 million. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. As a group, equities analysts anticipate that Hookipa Pharma will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Hookipa Pharma

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Hookipa Pharma by 22.6% during the first quarter. Vanguard Group Inc. now owns 1,118,871 shares of the company’s stock valued at $2,551,000 after purchasing an additional 206,309 shares during the period. State Street Corp increased its holdings in Hookipa Pharma by 29.3% in the 1st quarter. State Street Corp now owns 428,534 shares of the company’s stock worth $977,000 after acquiring an additional 97,057 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Hookipa Pharma by 117.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 87,217 shares of the company’s stock valued at $199,000 after acquiring an additional 47,168 shares during the period. Royal Bank of Canada raised its stake in Hookipa Pharma by 54.5% in the 1st quarter. Royal Bank of Canada now owns 255,883 shares of the company’s stock valued at $584,000 after acquiring an additional 90,232 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new stake in Hookipa Pharma during the first quarter valued at about $1,434,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $6.50 price target on shares of Hookipa Pharma in a report on Monday, March 25th. Royal Bank of Canada restated an “outperform” rating and issued a $5.00 target price on shares of Hookipa Pharma in a research note on Monday, March 25th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.